vs
Side-by-side financial comparison of Draganfly Inc. (DPRO) and Inhibikase Therapeutics, Inc. (IKT). Click either name above to swap in a different company.
Draganfly Inc. is the larger business by last-quarter revenue ($1.7M vs $1.0M, roughly 1.7× Inhibikase Therapeutics, Inc.). Draganfly Inc. runs the higher net margin — -409.2% vs -1223.3%, a 814.1% gap on every dollar of revenue.
Draganfly Inc. is a technology firm specializing in commercial drone design, manufacturing, and sales, plus supporting software and custom aerial data solutions. It serves public safety, agriculture, industrial inspection, disaster response, and mapping segments, with core North American markets and a global client base.
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel disease-modifying therapies for neurodegenerative disorders including Parkinson's disease. It advances pipeline candidates through preclinical and clinical studies to address unmet medical needs and improve patient outcomes worldwide.
DPRO vs IKT — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.7M | $1.0M |
| Net Profit | $-7.1M | $-12.7M |
| Gross Margin | 26.6% | — |
| Operating Margin | — | -1323.3% |
| Net Margin | -409.2% | -1223.3% |
| Revenue YoY | -8.7% | — |
| Net Profit YoY | -2.6% | -5.0% |
| EPS (diluted) | — | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.0M | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $1.7M | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | — | $-12.7M | ||
| Q3 25 | — | $-11.9M | ||
| Q2 25 | — | $-9.9M | ||
| Q1 25 | — | $-13.7M | ||
| Q4 24 | — | $-12.1M | ||
| Q3 24 | — | $-5.8M | ||
| Q2 24 | $-7.1M | $-5.0M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 26.6% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -1323.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -1223.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -409.2% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-0.10 | ||
| Q3 25 | — | $-0.13 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $0.88 | ||
| Q3 24 | — | $-0.65 | ||
| Q2 24 | — | $-0.66 | ||
| Q1 24 | — | $-0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3M | $218.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-2.6M | $172.9M |
| Total Assets | $9.9M | $181.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $218.3M | ||
| Q3 25 | — | $39.1M | ||
| Q2 25 | — | $9.9M | ||
| Q1 25 | — | $19.7M | ||
| Q4 24 | — | $138.6M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | $5.3M | $4.9M | ||
| Q1 24 | — | $7.4M |
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | $72.9M | ||
| Q2 25 | — | $80.1M | ||
| Q1 25 | — | $85.7M | ||
| Q4 24 | — | $94.9M | ||
| Q3 24 | — | $-530.6K | ||
| Q2 24 | $-2.6M | $5.1M | ||
| Q1 24 | — | $6.8M |
| Q4 25 | — | $181.2M | ||
| Q3 25 | — | $79.6M | ||
| Q2 25 | — | $88.9M | ||
| Q1 25 | — | $94.3M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $4.4M | ||
| Q2 24 | $9.9M | $8.8M | ||
| Q1 24 | — | $11.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-7.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-7.5M | ||
| Q3 25 | — | $-10.6M | ||
| Q2 25 | — | $-5.6M | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | $-5.3M | ||
| Q3 24 | — | $-4.9M | ||
| Q2 24 | — | $-5.1M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
